Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.

被引：0
|
作者：
Patnaik, Amita
Socinski, Mark A.
Gubens, Matthew A.
Gandhi, Leena
Stevenson, James
Bachman, Robert D.
Bourque, Jennifer
Ge, Joy Yang
Im, Ellie
Gadgeel, Shirish M.
机构：
[1] START, San Antonio, TX USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] UC San Francisco, San Francisco, CA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8011
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.
    Gubens, Matthew A.
    Sequist, Lecia V.
    Stevenson, James
    Powell, Steven Francis
    Villaruz, Liza Cosca
    Gadgeel, Shirish M.
    Langer, Corey J.
    Patnaik, Amita
    Borghaei, Hossein
    Jalal, Shadia Ibrahim
    Fiore, Joseph
    Ge, Joy Yang
    Raftopoulos, Harry
    Gandhi, Leena
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
    Papadimitrakopoulou, Vassiliki
    Patnaik, Amita
    Borghaei, Hossein
    Stevenson, James
    Gandhi, Leena
    Gubens, Matthew A.
    Yang, James Chih-Hsin
    Sequist, Lecia V.
    Ge, Joy Yang
    Bourque, Jennifer
    Bachman, Robert D.
    Im, Ellie
    Gadgeel, Shirish M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H
    Gubens, Matthew A.
    Sequist, Lecia V.
    Stevenson, James P.
    Powell, Steven F.
    Villaruz, Liza C.
    Gadgeel, Shirish M.
    Langer, Corey J.
    Patnaik, Amita
    Borghaei, Hossein
    Jalal, Shadia I.
    Fiore, Joseph
    Saraf, Sanatan
    Raftopoulos, Harry
    Gandhi, Leena
    LUNG CANCER, 2019, 130 : 59 - 66
  • [4] Pembrolizumab plus Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non-Small Cell Lung Cancer: KEYNOTE-021 Cohort G
    Langer, Corey
    Gadgeel, Shirish
    Borghaei, Hossein
    Papadimitrakopoulou, Vassiliki
    Patnaik, Amita
    Powell, Steve
    Gentzler, Ryan
    Martins, Renato
    Stevenson, James
    Jalal, Shadia
    Panwalkar, Amit
    Yang, James Chih-Hsin
    Gubens, Matthew
    Sequist, Lecia
    Fiore, Joseph
    Ge, Joy
    Raftopoulos, Harry
    Gandhi, Leena
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S391 - S392
  • [5] KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment
    Cummings, Amy Lauren
    Santoso, Kate M.
    Goldman, Jonathan W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (05) : 706 - 709
  • [6] Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001
    Soria, J. C.
    Flotten, O.
    Horn, L.
    Felip, E.
    Gandhi, L.
    Hui, R.
    Hellmann, M.
    Leighl, N.
    Zhang, J.
    Kondic, A.
    Rangwala, R.
    Lubiniecki, G. M.
    Garon, E. B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S726 - S727
  • [7] Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Balmanoukian, A. S.
    Rizvi, N. A.
    Garon, E. B.
    Patnaik, A.
    Gandhi, L.
    Leighl, N. B.
    Goldman, J. W.
    Eder, J. P.
    Johnson, E. A.
    Blumenschein, G. R.
    Gubens, M. A.
    Papadopoulos, K. P.
    Lubiniecki, G. M.
    Zhang, J.
    Niewood, M.
    Emancipator, K.
    Dolled-Filhart, M.
    Hanson, M. E.
    Hui, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S1 - S2
  • [8] Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Rizvi, Naiyer A.
    Garon, Edward B.
    Patnaik, Amita
    Gandhi, Leena
    Leighl, Natasha B.
    Balmanoukian, Ani Sarkis
    Goldman, Jonathan Wade
    Eder, Joseph Paul
    Johnson, Elizabeth
    Blumenschein, George R.
    Gubens, Matthew A.
    Papadopoulos, Kyriakos P.
    Lubiniecki, Gregory M.
    Zhang, Jin
    Niewood, Michelle
    Emancipator, Kenneth
    Dolled-Filhart, Marisa
    Hanson, Mary Elizabeth
    Hui, Rina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Initial report of a phase I study, MK3475-223
    Ben Nun, A.
    Golan, N.
    Ofek, E.
    Urban, D.
    Kamer, I.
    Simansky, D.
    Onn, A.
    Ackerstein, A.
    Raskin, S. P.
    Shulimzon, T.
    Zeitlin, N.
    Redinsky, I.
    Halperin, S.
    Jurkowicz, M.
    Bar, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
    Ohtsu, Atsushi
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Sun, Linda
    Wang, Zhen
    Csiki, Ildiko
    Koshiji, Minori
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345